Stock Analysis, Dividends, Split History

SYN / Synthetic Biologics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.09
Volume130,500.00
Market Cap ($M)273.92
Enterprise Value ($M)264.85
Book Value ($M)-6.49
Book Value / Share-0.05
Price / Book-42.23
NCAV ($M)2.99
NCAV / Share0.02
Price / NCAV91.55
Share Statistics
Common Stock Shares Outstanding 128,566,886
Common Shares Outstanding 128,566,886
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)10.36
Return on Assets (ROA)-0.69
Return on Equity (ROE)-4.03
Balance Sheet (mrq) ($M)
Assets8.42
Liabilities4.67
Quick Ration/a
Current Ratio1.77
Income Statement (mra) ($M)
Operating Income-26.25
Net Income-15.49
Earnings Per Share Basic-0.18
Earnings Per Share Basic And Diluted-0.18
Earnings Per Share Diluted-0.18
Cash Flow Statement (mra) ($M)
Cash From Operations-20.20
Cash from Investing-0.21
Cash from Financing-0.21
Identifiers and Descriptors
CUSIP87164U102
Central Index Key (CIK)894158

Split History

Stock splits are used by Synthetic Biologics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
SYN : Synthetic Biologics Stock Analysis and Research Report

2017-10-16 - Asif

Synthetic Biologics is a late-stage clinical stage company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). the companyare also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). Product Pipeline: ![](https://www.sec.gov/Archives/edgar/d...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Stocks To Watch: Any Privacy For Tesla?

2018-08-11 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (217-5)

Synthetic Biologics Inc. (SYN) Management on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good afternoon, everyone and welcome to the Synthetic Biologics 2018 Second Quarter Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded. (1-1)

Bloom Science Launches from Exclusive UCLA Tech License

2018-05-25 biospace
San Diego-based Bloom Science launched to develop epilepsy treatments based on a new class of neuroprotective drugs. The company, whose research was published in the journal Cell today, focuses on gut bacteria involved in the anti-seizure effects of the ketogenic diet. (104-0)

Synthetic Biologics' (SYN) Management on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good afternoon, and welcome to the Synthetic Biologics 2018 First Quarter Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded. (102-2)

BRIEF-Synthetic Biologics Reports Qtrly Loss Per Share $0.02

2018-05-08 reuters
* SYNTHETIC BIOLOGICS INC - QTRLY LOSS PER SHARE $0.02 Source text for Eikon: Further company coverage: (102-0)

CUSIP: 87164U102